Teva Presents Real-World Data for AUSTEDO® (deutetrabenazine) Tablets with 4-Week Patient Titration

START study provides real-world data for AUSTEDO with the use of a 4-week patient titration kit for adults with tardive dyskinesia (TD), including utilization and patient satisfactionAUSTEDO is the only vesicular monoamine transporter 2 (VMAT2) inhibitor with 3-year long-term data1,2 approved for adults with TD and...

Related Keywords

Andrew Cutler , Sanjeev Sharma , Eric Hughes , Yael Ashman , Drug Administration , Psych Congress Elevate , Neuroscience Education Institute , Teva Pharmaceuticals , Subcutaneous Administration Olanzapine For , Teva Pharmaceutical Industries Ltd , Teva Pharmaceutical Industries , Executive Vice President , Chief Medical Officer , Clinical Global Impression , Patient Global Impression , Associate Clinical Professor , Medical University , Neuroscience Education , Sample Titration Kit , Poster Presentations , Real World Effectiveness , Deutetrabenazine When Initiated Using , Week Patient Titration Kit , Interim Results , Patient Satisfaction With , Patient Titration Kit , Population Estimate , Patients With Tardive Dyskinesia , Real World Clinical Practice , Across Age Groups , Underlying Psychiatric Conditions , Payer Types , Healthcare Professional Perspectives , Key Impacts , Tardive Dyskinesia , Long Acting Subcutaneous Antipsychotic , Local Tolerability , Injection Site Reactions , Long Term Safety , Patients With Schizophrenia , Double Blind Study , Placebo Controlled Trial Assessing Safety , Subcutaneous Administration , Extended Release Injectable Suspension Use , Adults With Schizophrenia , Patient Characteristics , Transitioning Patients , Long Acting Injectable Antipsychotics , Hypothetical Case , Initiating Long Acting Injectable Antipsychotics , Release Tablets , Adverse Events , Malignant Syndrome , Melanin Containing Tissues , Adverse Reactions , Prescribing Information , Motor Impairment ,